Vista Pharmaceuticals Current Share Price | Vista Pharmaceuticals Stock Screener
VISTAPH
Pharmaceuticals
Vista Pharmaceuticals Current Stock Price Today
Live Share Price BSE
₹5.88
▲
0.27 (4.81%)
As of September 18, 2026, the live Vista Pharmaceuticals share price (BSE: VISTAPH) is ₹5.88, up 4.81% from the previous close, with shares trading between ₹5.62 and ₹5.99 in today's trading session, and a 52-week range of ₹5.36–₹10.24.
Browse VISTAPH annual financials to support your investment research.
Use the Vista Pharmaceuticals stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Vista Pharmaceuticals Market Cap
₹35.42 Cr.
VISTAPH P/E Ratio (TTM)
-2.93
Vista Pharmaceuticals P/B Ratio
0.95
EPS (TTM)
₹-1.96
Dividend Yield
-
Debt to Equity
0.18
VISTAPH 52 Week High
₹10.24
Vista Pharmaceuticals 52 Week Low
₹5.36
Operating Margin
-90.00%
Profit Margin
-300.00%
VISTAPH Revenue (TTM)
₹4.00
EBITDA
₹-14.00
Net Income
₹-12.00
Total Assets
₹55.00
Total Equity
₹36.00
Vista Pharmaceuticals Current Share Price Chart
Track the current Vista Pharmaceuticals share price and stock price with an interactive chart. Analyse VISTAPH price trends, trading volume, historical performance, and volatility across different timeframes — the complete Vista Pharmaceuticals stock quote in one place.
Vista Pharmaceuticals Company Profile - Fundamental Screener
Screen Vista Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for VISTAPH shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE427C01021
Vista Pharmaceuticals Balance Sheet Screener
Screen VISTAPH balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 55 | 60 | 58 | 56 | 56 | 51 | 51 | 53 | 53 | 42 |
| Current Assets | 15 | 25 | 23 | 24 | 24 | 15 | 21 | 23 | 28 | 26 |
| Fixed Assets | 29 | 19 | 19 | 20 | 19 | 20 | 21 | 21 | 18 | 14 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 2 | 3 | 3 | 5 | 8 | 9 | 6 | 6 | 6 | 6 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 36 | 45 | 41 | 37 | 36 | 33 | 30 | 36 | 32 | 17 |
| Share Capital | 12 | 12 | 9 | 8 | 7 | 7 | 6 | 6 | 6 | 5 |
| Reserves & Surplus | 24 | 33 | 26 | 23 | 28 | 26 | 24 | 30 | 26 | 11 |
Vista Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Vista Pharmaceuticals income statement and profit fundamentals.
Analyze VISTAPH quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Vista Pharmaceuticals share price evaluation.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4 | 5 | 11 | 11 | 1 | 1 | 2 | 27 | 34 | 29 | 24 | 15 | 14 |
| Expenses | 18 | 20 | 14 | 14 | 5 | 2 | 3 | 28 | 30 | 24 | 21 | 13 | 11 |
| EBITDA | -14 | -15 | -4 | -3 | -4 | -1 | -2 | -1 | 4 | 6 | 3 | 3 | 3 |
| Operating Profit % | -90.00% | -271.00% | -40.00% | -32.00% | -443.00% | -321.00% | -137.00% | -21.00% | 4.00% | 18.00% | 13.00% | 17.00% | 20.00% |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 0 |
| Profit Before Tax | -16 | -16 | -5 | -5 | -6 | -3 | -4 | -4 | 1 | 3 | 1 | 1 | 1 |
| Tax | 0 | 0 | -1 | -1 | 0 | -2 | -2 | 0 | 0 | 1 | 0 | 0 | 0 |
| Net Profit | -12 | -16 | -5 | -5 | -6 | -1 | -2 | -4 | 1 | 2 | 1 | 1 | 1 |
| EPS | -1.90 | -1.96 | -0.79 | -1.03 | -1.54 | -0.24 | -0.54 | -1.22 | 0.31 | 0.76 | 0.46 | 0.31 | 0.54 |
Vista Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen VISTAPH cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | -7 | -5 | -2 | -1 | -7 | 1 | 3 | -5 | 3 | -3 |
| Investing Activities | 0 | -1 | -1 | 0 | 0 | -2 | -6 | -11 | -4 | 0 |
| Financing Activities | 8 | 6 | 3 | 1 | 7 | 0 | 1 | 11 | 6 | 3 |
| Net Cash Flow | 1 | 0 | 0 | 0 | 0 | -1 | -1 | -4 | 5 | 0 |
Vista Pharmaceuticals Shareholding Pattern Screener
See Vista Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Vista Pharmaceuticals promoter holding and ownership changes for VISTAPH on TickJournal.
| Item | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% | 21.19% |
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 33.63% | 33.63% | 33.63% | 33.64% | 33.62% | 33.62% | 34.00% | 33.86% |
| Other Holding | 45.17% | 45.17% | 45.16% | 45.16% | 45.17% | 45.17% | 44.79% | 44.93% |
| Shareholder Count | 14,154 | 14,154 | 14,080 | 14,012 | 14,061 | 14,158 | 14,086 | 13,913 |
Vista Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Vista Pharmaceuticals dividend history with payout and yield data.
View Vista Pharmaceuticals dividend details including ex-dates and amounts for VISTAPH stock.
Vista Pharmaceuticals Stock Index Membership
See which indices include Vista Pharmaceuticals stock.
Check VISTAPH index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Vista Pharmaceuticals Market Events Screener - Corporate Actions
Get Vista Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Vista Pharmaceuticals stock events that may affect VISTAPH share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-08-14 | 2026-08-14 | Quarterly Result Announcement | NA | 1.17% |
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | 10.19% |
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | -6.06% |
| 2025-11-13 | 2025-11-13 | Quarterly Result Announcement | NA | -0.83% |
| 2025-09-30 | 2025-09-30 | Annual General Meeting | NA | -12.39% |
| 2025-08-13 | 2025-08-13 | Quarterly Result Announcement | NA | 4.83% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -0.27% |
| 2025-03-20 | 2025-03-20 | Extraordinary General Meeting | NA | -0.65% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | 11.02% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | -1.49% |
| 2024-09-30 | 2024-09-30 | Annual General Meeting | NA | 4.18% |
| 2024-03-06 | 2024-03-06 | Extraordinary General Meeting | NA | -9.45% |
Vista Pharmaceuticals Competitors Screener - Peer Comparison
Screen VISTAPH competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 441,478 | 36.91 | 61,674 | 12.69% | 11,565 | 34.00 |
| Divis Laboratories | 247,470 | 85.36 | 11,067 | 13.95% | 2,568 | 63.65 |
| Torrent Pharmaceuticals | 188,872 | 86.95 | 13,886 | 20.34% | 2,138 | 52.16 |
| Zydus Life Science | 112,608 | 24.28 | 27,658 | 17.64% | 5,026 | 45.64 |
| Cipla | 110,352 | 33.22 | 29,045 | 2.24% | 3,870 | 35.27 |
| Laurus Labs | 106,298 | 95.94 | 6,868 | 22.01% | 890 | 68.28 |
| Dr Reddys Laboratories | 97,281 | 29.91 | 35,059 | 3.90% | 4,158 | 47.72 |
| Aurobindo Pharma | 96,652 | 25.88 | 34,145 | 5.56% | 3,503 | 57.04 |
| Lupin | 95,790 | 17.09 | 29,039 | 26.75% | 5,356 | 28.17 |
| Mankind Pharma | 94,163 | 44.87 | 14,636 | 14.85% | 1,938 | 37.57 |
Vista Pharmaceuticals Company Announcements - News Screener
Screen VISTAPH latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-09-19 | Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer | - |
| 2026-08-14 | Board Meeting Outcome for Results For The Quarter Ended 30.06.2026 | - |
| 2026-08-14 | Results For The Quarter Ended 30.06.2026 | - |
| 2026-08-13 | Board Meeting Intimation for Approval Of Un Audited Financials Results For The Quarter Ended 30.06.2026 | - |
| 2026-07-15 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-06-25 | Closure of Trading Window | - |
| 2026-05-29 | Compliances-Reg.24(A)-Annual Secretarial Compliance | - |
| 2026-05-29 | Outcome Of Board Meeting Under Regulations 30 Read With 33 (3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-05-19 | Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ended 31.03.2026 | - |
| 2026-04-29 | Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 | - |
| 2026-04-14 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-27 | Closure of Trading Window | - |
| 2026-02-13 | Board Meeting Outcome for Un Audited Financial Results For The Quarter Ended 31.12.2025 | - |
| 2026-02-13 | Results For The Quarter Ended 31.12.2025 | - |
| 2026-02-05 | Update on board meeting | - |
| 2026-02-05 | Board Meeting Intimation for 1. Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2025. 2. Limited Review Report Quarter And Nine Months 31.12.2025. 3. Any Other Business With The Permission Of The Chair. | - |
| 2026-02-03 | Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Joint Venture Partnership Between Pleiades Therapeutics And Vista Pharmaceuticals Ltd | - |
| 2026-01-13 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-30 | Closure of Trading Window | - |
| 2025-11-13 | Board Meeting Outcome for Un Audited Financial Results For The Quarter And Half Year Ended 30.09.2025 | - |